Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CEO Emil D. Kakkis Sells 73,434 Shares

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CEO Emil D. Kakkis sold 73,434 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total value of $3,091,571.40. Following the sale, the chief executive officer now owns 641,731 shares in the company, valued at approximately $27,016,875.10. This trade represents a 10.27 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Ultragenyx Pharmaceutical Stock Performance

Ultragenyx Pharmaceutical stock traded down $0.16 during midday trading on Tuesday, reaching $41.10. 1,385,598 shares of the company’s stock were exchanged, compared to its average volume of 779,217. Ultragenyx Pharmaceutical Inc. has a 52 week low of $37.02 and a 52 week high of $60.37. The firm has a market cap of $3.80 billion, a price-to-earnings ratio of -6.48 and a beta of 0.60. The stock’s 50-day simple moving average is $42.86 and its 200 day simple moving average is $49.03.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.32) by ($0.07). The company had revenue of $164.88 million for the quarter, compared to analyst estimates of $163.23 million. Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. Research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Wedbush restated a “neutral” rating and set a $48.00 price target (up from $46.00) on shares of Ultragenyx Pharmaceutical in a research report on Monday, January 13th. Wells Fargo & Company increased their price target on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an “overweight” rating in a research note on Friday, December 20th. Piper Sandler increased their price target on Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the company an “overweight” rating in a research note on Monday, January 13th. JPMorgan Chase & Co. dropped their price objective on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating on the stock in a research note on Thursday, November 21st. Finally, Canaccord Genuity Group raised their price objective on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a “buy” rating in a research note on Tuesday, February 18th. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $93.50.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Hedge funds and other institutional investors have recently made changes to their positions in the business. International Assets Investment Management LLC increased its stake in Ultragenyx Pharmaceutical by 29,580.0% in the third quarter. International Assets Investment Management LLC now owns 10,388 shares of the biopharmaceutical company’s stock valued at $577,000 after acquiring an additional 10,353 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Ultragenyx Pharmaceutical by 34.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,333 shares of the biopharmaceutical company’s stock valued at $181,000 after acquiring an additional 851 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in Ultragenyx Pharmaceutical by 195.6% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 21,753 shares of the biopharmaceutical company’s stock valued at $1,208,000 after acquiring an additional 14,394 shares during the last quarter. Principal Financial Group Inc. increased its stake in Ultragenyx Pharmaceutical by 740.0% in the third quarter. Principal Financial Group Inc. now owns 86,440 shares of the biopharmaceutical company’s stock valued at $4,802,000 after acquiring an additional 76,150 shares during the last quarter. Finally, Capital Performance Advisors LLP bought a new position in Ultragenyx Pharmaceutical in the third quarter valued at approximately $107,000. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.